Do Payers Pay More If Drug Risks Are Not Disclosed? GSK Seeks Supreme Court Answer
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline petitions court to review third party payers' RICO claims in Avandia litigation; PhRMA cites 'growing torrent' of such suits against drug makers.
You may also be interested in...
Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.
Supreme Court Rejects Most Pharma Cases This Term, But Patent Settlements Stir Interest
High court seeks Solicitor General's view on whether patent settlements blocking authorized generics are anticompetitive; court denies GSK petition challenging payer claims in Avandia litigation.